A Prospective Open-Label Study of the Effectiveness of Epoetin Beta for Treating Anemic Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS)
Phase of Trial: Phase IV
Latest Information Update: 25 Apr 2019
Price : $35 *
At a glance
- Drugs Epoetin beta (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Roche
- 23 Apr 2019 Status changed from active, no longer recruiting to completed.
- 30 Jan 2019 Planned End Date changed from 30 Jun 2019 to 12 Apr 2019.
- 30 Jan 2019 Planned primary completion date changed from 30 Jun 2019 to 12 Apr 2019.